Grants for Nonprofits - Federal

This Notice of Intent to Publish is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects for the following Notice of Funding Opportunity (NOFO), which is expected to be published in January 2024, with an anticipatedapplication receipt date in May 2024. The Brain Research through Advancing Innovative Neurotechnologies(BRAIN) Initiative intends to promote a new initiative by publishing a NOFO to solicit applications that would support development and preclinical testing, beginning withproof of concept,of next-generation recording and/or modulation devices for human use to further our understanding of the human central nervous system and treat nervous system disorders. This NOFO will utilize the R18 activity code. Details of the planned NOFO are provided below.

This funding opportunity provides financial support to organizations that aim to improve services for older adults with behavioral health issues in senior nutrition programs, focusing on creating accessible and culturally sensitive practices.

The FY24 VRP MCRA is intended to support patient-oriented vision injury research and develop research expertise of highly motivated military or civilian clinicians in training. Research supported by the MCRA can be a standalone study of high impact to vision injury care or the generation of clinical research data in preparation for a more expansive study.Each MCRA must be led by an established clinician or Ph.D. clinical scientist who will serve as Principal Investigator (PI) of the award. Key personnel must include a clinician in training (e.g., a fellow, resident, junior clinician, clinician in a Ph.D. program). The clinician in training should have sufficient time remaining in their training program to complete the research proposed under the MCRA. The clinician in training will conduct the proposed research under the mentorship of the PI, with support from supporting personnel as appropriate. While additional junior scientists or clinicians may participate in the research, only one clinician in training may be designated as mentee. A Letter of Organizational Support and Mentee Eligibility, signed by the Department Chair or appropriate organization official, and a Letter of Commitment, signed by the mentee, should be submitted as part of Attachment 2: Supporting Documentation.For the purposes of this award mechanism, clinical research is defined as research conducted with human subjects or research on material of human origin, such as tissues or specimens or data obtained from human subjects. Documentation of Institutional Review Board (IRB)/ Ethics Committee (EC) approval or exemption by December 1, 2024, is required for an MCRA application to be considered for funding. See Attachment 2: Supporting Documentation for additional detail.The MCRA may not be used to conduct preclinical research (including animal research) or clinical trials.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Studies that retrospectively analyze data generated from previously conducted clinical trial(s) are not considered a clinical trial.

President Bidens Inflation Reduction Act authorized the U.S. Environmental Protection Agency (EPA) to implement the Greenhouse Gas Reduction Fund (GGRF), a historic $27 billion investment to combat the climate crisis by mobilizing financing and private capital for greenhouse gas- and air pollution-reducing projects in communities across the country. As part of this program, EPA is launching a $7 billion Solar for All competition designed to spur the deployment of residential distributed solar energy to lower energy bills for millions of Americans and catalyze transformation in markets serving low-income and disadvantaged communities. Solar for All will tackle the financial and non-financial barriers that limit the ability of low-income and disadvantaged communities across the country to benefit from the rapid growth in distributed solar capacity, thus advancing the Biden-Harris Administrations climate and environmental justice goals. This Notice of Funding Opportunity (NOFO) is for the $7 billion Solar for All competition. This competition will award up to 60 grants to states, territories, Tribal governments, municipalities, and eligible nonprofit recipients to expand the number of low-income and disadvantaged communities primed for distributed solar investmentenabling millions of low-income households to access affordable, resilient, and clean solar energy. Grantees will use funds to expand existing low-income solar programs or design and deploy new Solar for All programs nationwide. EPA will not fund individual projects under this competition. EPAs $7 billion Solar for All competition will help deliver on the climate and environmental justice goals of the United States. To achieve these goals, Solar for All grantees will provide subsidies and other financial assistance to residential rooftop and residential-serving community solar projects in and benefiting low-income and disadvantaged communities in addition to project-deployment technical assistance such as workforce development, community outreach, and other project-deployment support (e.g., interconnection technical assistance, siting and permitting support) to help overcome barriers to solar deployment.

The United States Agency for International Development (USAID) is issuing this Broad Agency Announcement (BAA) to seek participants to co-create, co-design, co-invest, and collaborate on creating, piloting, and scaling innovative research and development interventions utilizing innovative health practices to help reduce disease and mortality rates worldwide. USAID invites organizations and companies to submit an Expression of Interest (EOI) and participate in generating novel tools and approaches that accelerate and sustain improved health outcomes in low-and-middle-income countries (LMICs). The intent of the BAA is to allow co-creation and co-design to the maximum extent to create high quality, effective partnerships with great efficiency in time and resources. USAID is seeking new applications of research development, science, partnerships, and innovative practices in global health that provide the best value to the Government. USAID will invite selected for-profit and non-profit, public and private organizations, as detailed below, to co-create innovative research and development (R) solutions to the Problem and Challenge Statements stated in this BAA, including those organizations that have ideas, expertise, resources, and/or funding to add to potential solutions. In particular, this BAA welcomes co-creation from local partners based in LMICs, including the private sector, faith-based organizations, and other non-traditional USAID partners, to increase the presence and voices of local populations in solving their own health challenges.The intent of the BAA is to enable and encourage co-creation and co-design in order to generate high quality ideas and effective partnerships with improved efficiency in time and resources. Other types of collaboration can also include co-investing:Co-Investing: USAID wants to align goals with the partners under this BAA, to facilitate shared responsibility, shared risk, and shared resourcing. Shared resourcing requires that cash and other resources, both tangible and intangible, such as in-kind contributions, expertise, intellectual property, brand value, high-value coordination, and access to key people, places, and information, are directed towards reaching the solution to the Problem/Challenge. Co-investing does not require equal shared resources (such as 1:1 leverage), but rather resource contributions that are appropriate to the specific projects objectives, considering the comparative advantages brought by the participation of each party.

This funding opportunity invites researchers to develop and apply advanced imaging techniques to better understand the role of inflammation in cancer, fostering collaboration between cancer scientists and imaging experts.

This funding opportunity supports research training for underrepresented students and health professionals in cardiovascular, pulmonary, hematologic diseases, and sleep disorders, aiming to increase diversity in the biomedical research workforce and reduce health disparities.

This Funding Opportunity Announcement (FOA) allows for renewal and competitive revision applications, and their resubmissions, for funded U24?Research Resource/Infrastructure?applications?that?support?large-scale, complex research programs focused on?Alzheimers disease (AD) and?Alzheimers disease-related dementias (ADRD).?It is anticipated that such programs will likely involve a team of investigators within a single institution or a consortium of?institutions?and?align with one or more?AD/ADRD implementation research milestones?supporting the?research goals of the??National Plan to Address Alzheimers and Related Dementias.

This funding opportunity supports U.S. and Luxembourgish organizations in initiatives that strengthen security and defense collaboration, focusing on NATO, countering misinformation, and enhancing cybersecurity efforts.

The FY 2024 Teams Engaging Affiliated Museums and Informal Institutions (TEAM II) STEM Innovator Award is a grant offered by NASA's Next Gen STEM Project, aimed at supporting informal education organizations and libraries in providing NASA-aligned, inquiry-based STEM educational opportunities to students and educators, with the goal of expanding their regional reach, enhancing innovative practices, and benefiting diverse local communities.

The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorder (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. NIDA expects these studies to uncover novel mechanisms that contribute to SUD and facilitate the discovery of targets for intervention and guide the development of individualized therapeutics to treat these different aspects of SUD.

This funding opportunity provides financial support for research and evaluation projects aimed at improving malaria control and prevention strategies in Kenya, specifically targeting collaborations with local health institutions.

This funding opportunity provides financial support for innovative research in advanced scientific computing and extreme-scale science, targeting a wide range of applicants including universities, for-profit companies, and federal laboratories, to tackle challenges in high-performance computing, quantum technologies, and artificial intelligence.

This funding opportunity provides financial support to early-career researchers who have received specific NIAMS awards, enabling them to conduct small-scale studies and gather data to advance their research and secure future funding.

This grant provides funding for experienced researchers at U.S. higher education institutions to explore new engineering fields or reestablish their research after a break, with a focus on innovation, societal impact, and promoting diversity and inclusion.

The overall goal of ProCON Global is to promote open, interoperable, reliable, and secure commercial undersea cable systems around the world. The project will provide technical assistance to key decision-makers, including policymakers, regulators, and technology companies in emerging economies, to promote evaluation processes and investment in secure and trusted vendors when establishing undersea cable network supply chains. Technology companies include telecommunications operators/carriers, major technology and security firms, innovators, and content and cloud providers.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a fundamentally new approach that is significantly more effective than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the program announcement, and not on the amount of the budget.The current program announcement discusses the Breakthrough Award Level 3. Funding Levels 1, 2, and 4 are available under other program announcements (HT942524BCRPBTA12 for Levels 1 and 2 and HT942524BCRPBTA4 for Level 4). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award program announcements before submitting the pre-application. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.The following is a general description, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current program announcement:Funding Level 3: Advanced translational studies with a high degree of project readiness. Where relevant, proof of availability of and access to necessary data, human samples, cohort(s), and/or critical reagents must be provided. If the proposed research would ultimately require U.S. Food and Drug Administration (FDA) involvement, applications must demonstrate availability of, and access to, clinical reagents (e.g., therapeutic molecules) and patient population(s). Applications must state a realistic timeline for near-term clinical investigation. Small-scale clinical trials (e.g., first in human, phase 1/1b) may be appropriate.Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. New partnerships are encouraged, but not required. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from being named as a Partnering PI on multiple Breakthrough Award Level 3 applications unless they are clearly addressing distinct research questions. Applications where one PI is providing samples, animal models, or investigational agents while the other PI is conducting most or all of the experiments and analyses do not meet the intent of the Partnering PI Option. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Consumer Advocates: Applications are required to include consumer advocate involvement. The research team must include two or more breast cancer consumer advocates, who will be integral throughout the planning and implementation of the research project. Consumer advocates should be involved in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer, and they should be active in a breast cancer advocacy organization. Their role in the project should be independent of their employment, and they cannot be employees of any of the organizations participating in the application. Their role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, breast cancer. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Level 3 should not exceed $4M for applications with a single PI or $5M if applying under the Partnering PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $13.95M to fund approximately two BCRP Breakthrough Award Level 3 applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

Under the authority of Section 21 of the Occupational Safety and Health Act of 1970 (OSH Act), the U.S. Department of Labor (DOL) Occupational Safety and Health Administration (OSHA) established its discretionary grant program in 1978. In 1997, OSHA renamed the program in honor of the late Susan Harwood, former director of the OSHA Office of Risk Assessment. The grant program offers opportunities for nonprofit organizations to compete annually for funding so they may develop and conduct training and educational programs for small business employers and workers. The Susan Harwood Training Grant Program aims to advance the job quality of the American workforce by providing disadvantaged, underserved, low-income, or other hard-to-reach, at-risk workers with hazard awareness, avoidance, and control training to protect them from on-the-job hazards, and to inform workers of their rights and employers of their responsibilities under the OSH Act. The program and this funding opportunity announcement prioritizes investment and funding to train workers and employers impacted by working in high-hazard industries, industries with high fatality rates, or whose workforce has historically had disadvantaged access to occupational safety and health training, including young workers, temporary, minority, low literacy, limited-English speaking, and other disadvantaged and hard-to-reach workers and worker communities. The Susan Harwood Training Grant Program seeks to increase access to life-saving training by encouraging grantees to provide the training in other languages. Technical assistance, guidance, and support for this funding opportunity is presented in OSHAs FY 2024 Susan Harwood Training Grant Funding Opportunity Overview available at: www.osha.gov/harwoodgrants/applicant-information. The program is designed to support and enable nonprofit organizations efforts to provide this important occupational safety and health training to disadvantaged workers. These nonprofit organizations include qualifying labor unions, community-based, faith-based, and grassroots organizations; employer associations; Native American tribes; tribal Alaska Native, Native Hawaiian, and native-controlled organizations that are not an agency of a state or local government; and public/state-controlled institutions of higher education. The program provides education and training on advancement of workers workplace rights and protections against discrimination and reprisal. The Susan Harwood Training Grant Program seeks applications based on proven strategies to reach the target training populations while also developing innovative solutions to expand access. Grantees agree to participate in the data collection and training impact evaluations described in this funding opportunity announcement. The Susan Harwood Grant Program awards funds to qualifying organizations who have demonstrated capabilities to achieve the programs performance expectations outlined in this FOA. This includes experience in employing subject matter experts, delivering and administering adult training programs, recruiting students, and managing grants. Following the grant awards, OSHA monitors each organizations progress in achieving their performance goals and training targets. OSHA accomplishes this by conducting orientation meetings, training material reviews, training observations, program and financial monitoring visits, and quarterly and year-end report reviews. For FY 2024, OSHA announces the availability of $12,787,000 in funding for new Susan Harwood Training Program grants based on 2024 federal appropriations. OSHA expects to award multiple grants to eligible nonprofit organizations under this competitive FOA. This FOA does not itself obligate any federal funds. The obligation of funds occurs when grant recipients acknowledge receipt and acceptance of award documents. Program funding is for a 12-month period beginning no later than September 30, 2024, and ending on September 30, 2025. The maximum award for a Training and Educational Materials Development grant is $75,000. Applications submitted under this FOA are competing for a Training and Educational Materials Development grant. This FOA does not itself obligate any federal funds. The obligation of funds occurs when grant recipients acknowledge receipt and acceptance of award documents. Applicants must propose to develop new training materials addressing one of the OSHA-specified training topics. The materials must include learning objectives, course matrices, presentation/training materials including videos, instructor and participant guides, student handouts, training evaluations, and learning assessments. Grantees must validate the training materials by conducting a pilot instructor-led classroom training session. Organizations are restricted to one Susan Harwood Targeted Topic Training grant, Training and Educational Materials Development grant, or Capacity Building grant award in a fiscal year. If an organization submits multiple applications for any of these Susan Harwood funding opportunities, OSHA will review the last complete and viable application package submitted. Once submitted, applications are not available for additions, corrections, or revisions. To make changes to a submitted application, the organization must submit a new application package. This FOA closes on July 26, 2024, at 11:59 p.m. eastern time. Applications not validated www.grants.gov (Grants.gov), or submitted after this deadline, are ineligible for consideration.

FMPP funds projects that develop, coordinate, and expand direct producer-to-consumer markets to help increase access to and availability of locally and regionally produced agricultural products. The program focuses on: Supporting and promoting domestic direct producer-to-consumer (including direct producer-to-retail, direct producer-to-restaurant, and direct producer-to-institutional marketing) marketing such as farmers markets, roadside stands, agritourism activities, community-supported agriculture (CSA) programs, or online sales; Encouraging the development of value-added agricultural products; Developing marketing strategies for producers of local food and value-added products; Facilitating regional food chain coordination development; Promoting new business opportunities and marketing strategies to reduce on-farm food waste; Responding to changing technology needs in direct producer-to-consumer marketing; and Covering expenses related to costs incurred in obtaining food safety certification and improvements to food safety practices and equipment.

This funding opportunity supports research to develop and test behavioral interventions aimed at reducing sexual risk behaviors and increasing the use of HIV prevention methods among HIV-negative Black and Hispanic men who have sex with men and use substances before or during sex.